



The Crucial Involvement of CD8 in HIV Progression: A Review

***Emmanuel Ifeanyi Obeagu¹ and Getrude Uzoma Obeagu²**

¹Department of Medical Laboratory Science, Kampala International University, Uganda.

²School of Nursing Science, Kampala International University, Uganda.

*Corresponding author: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com, ORCID: 0000-0002-4538-0161

Abstract

The relentless global impact of Human Immunodeficiency Virus (HIV) underscores the urgency of understanding the intricate immune responses involved in its progression. CD8 T cells play a central role in orchestrating the immune defense against HIV, wielding the potential to both curtail viral replication and, paradoxically, succumb to exhaustion. This comprehensive review explores the multifaceted engagement of CD8 T cells in HIV pathogenesis. It encompasses the mechanisms underlying CD8 T cell recognition, the protective effects they exert, factors influencing their efficacy, and the emerging landscape of CD8-focused therapeutic interventions. Delving into the delicate balance between immune defense and viral evasion, this review seeks to provide a nuanced understanding of CD8 T cell involvement in HIV progression and illuminate the prospects for future therapeutic advancements.

Keywords: HIV, CD8 T cells, protective effects.

Introduction

Human Immunodeficiency Virus (HIV) continues to be a global health challenge, affecting millions of individuals worldwide and necessitating ongoing efforts to unravel the intricacies of the immune responses involved in its progression. Among the diverse immune players, CD8 T cells have emerged as pivotal contributors in the battle against HIV. The intricate dance between the virus and these immune guardians underscores the need for a comprehensive exploration of the

crucial involvement of CD8 T cells in HIV progression. CD8 T cells, also known as cytotoxic T lymphocytes, play a central role in immune surveillance, specifically targeting cells infected with intracellular pathogens, including viruses. Their significance in the context of HIV lies in their ability to recognize and eliminate infected cells, thereby limiting viral replication and disease progression. However, the relationship between CD8 T cells and HIV is dynamic, characterized by a delicate balance between protective functions and the potential for immune exhaustion.¹⁻²⁵

This paper aims to provide a thorough examination of the multifaceted roles played by CD8 T cells in the context of HIV infection. We will delve into the mechanisms underlying CD8 T cell recognition of HIV, the protective effects they confer, and the factors influencing their efficacy. Furthermore, we will explore the nuances of CD8 T cell exhaustion, a phenomenon that can compromise their ability to control viral replication over time. As our understanding of the interplay between CD8 T cells and HIV deepens, so does the potential for developing targeted therapeutic interventions. The latter part of this review will highlight current and emerging strategies aimed at harnessing the power of CD8 T cells for HIV treatment, offering a glimpse into the future of personalized and effective therapeutic approaches.²⁶⁻³⁶

CD8 T Cell Recognition of HIV

The battle between the human immune system and Human Immunodeficiency Virus (HIV) hinges significantly on the ability of CD8 T cells to recognize and respond to the virus. This section will delve into the intricate mechanisms underlying CD8 T cell recognition of HIV, highlighting the processes that allow these immune sentinels to identify and eliminate virus-infected cells. CD8 T cell recognition begins with the presentation of viral antigens. Infected cells display short peptides derived from viral proteins on their surfaces using major histocompatibility complex class I (MHC-I) molecules. This antigen presentation is a crucial step, allowing CD8 T cells to scan for signs of viral infection. The T cell receptor (TCR) on CD8 T cells recognizes specific peptide-MHC-I complexes. When a CD8 T cell encounters an infected cell displaying HIV peptides, the TCR binds to the MHC-I-peptide complex, initiating a signaling cascade within the T cell. This engagement is highly specific and enables the CD8 T cell to discriminate between infected and uninfected cells.³⁷⁻⁴⁷

Recognition alone is insufficient for CD8 T cell activation. Co-stimulatory signals, provided by molecules like CD28 on the T cell interacting with CD80/CD86 on the antigen-presenting cell, are necessary for full T cell activation. Upon

receiving these signals, CD8 T cells become activated and undergo clonal expansion to generate a population of effector cells. Activated CD8 T cells then exert their effector functions. They release cytotoxic molecules such as perforin and granzymes, inducing apoptosis in the infected cell. Additionally, CD8 T cells can secrete antiviral cytokines like interferon-gamma (IFN- γ), which further contribute to controlling viral replication. Following the elimination of infected cells, a subset of CD8 T cells transforms into memory cells, providing long-lasting immunity. Memory CD8 T cells can respond more rapidly upon re-encountering the virus, offering a heightened defense mechanism. Despite the effectiveness of CD8 T cell recognition, HIV has developed strategies to evade immune surveillance. The virus can mutate rapidly, leading to the emergence of escape variants that may not be effectively recognized by existing CD8 T cell populations. Additionally, HIV employs mechanisms to hinder the proper activation of CD8 T cells, contributing to viral persistence.⁴⁸⁻⁵⁹

Protective Effects of CD8 T Cells

CD8 T cells serve as the vanguard of the immune response against Human Immunodeficiency Virus (HIV), wielding potent mechanisms to control viral replication and mitigate disease progression. One of the primary protective functions of CD8 T cells is their ability to directly eliminate cells infected with HIV. Upon recognizing viral antigens presented on the surface of infected cells, activated CD8 T cells release cytotoxic molecules such as perforin and granzymes. Perforin creates pores in the target cell membrane, allowing granzymes to enter and induce apoptosis, effectively eliminating the infected cell. CD8 T cells contribute to the antiviral milieu by releasing cytokines, with interferon-gamma (IFN- γ) being a key player. IFN- γ has multiple antiviral effects, including inhibiting viral replication within infected cells, enhancing the activity of other immune cells, and promoting an antiviral state in surrounding cells. This cytokine-mediated response adds an additional layer of defense against HIV. CD8 T cells play a crucial role in limiting the spread of

HIV within the host. By eliminating infected cells and secreting antiviral cytokines, CD8 T cells help contain viral replication, preventing widespread dissemination. This containment is vital for controlling the viral load and delaying disease progression.⁶⁰⁻⁷⁰

Apart from the classical cytotoxic mechanisms, CD8 T cells employ alternative strategies to control HIV. These include the activation of cellular antiviral pathways and the release of non-cytotoxic factors, collectively contributing to the overall antiviral state. CD8 T cells often exhibit polyfunctionality, producing multiple effector molecules simultaneously. This polyfunctional response enhances their ability to combat HIV. Moreover, CD8 T cells synergize with other components of the immune system, such as CD4 T cells and antibody-producing B cells, to mount a coordinated and robust antiviral response. Successful encounters with HIV result in the formation of memory CD8 T cells. These cells persist in the immune system, ready to mount a rapid and targeted response upon re-exposure to the virus. The establishment of a memory CD8 T cell pool contributes to long-term immune protection.⁷¹⁻⁷²

Factors Influencing CD8 Efficacy

The effectiveness of CD8 T cells in controlling Human Immunodeficiency Virus (HIV) is influenced by a multitude of factors that shape the dynamics of the immune response. Genetic variability among individuals plays a significant role in CD8 T cell efficacy. Polymorphisms in genes associated with MHC-I molecules, which present viral antigens to CD8 T cells, can influence the ability of CD8 T cells to recognize and respond to HIV. Additionally, genetic variations in cytokines and immune response genes may impact the overall effectiveness of the CD8 T cell-mediated immune response. The diversity and heterozygosity of Human Leukocyte Antigen (HLA) genes, which encode MHC molecules, contribute to the breadth of antigens that CD8 T cells can recognize. Higher HLA diversity and heterozygosity are associated with improved control of HIV, highlighting the importance of a broad immune response in

restricting viral escape. HIV is notorious for its ability to mutate rapidly, leading to the emergence of variants that can escape recognition by CD8 T cells. These viral escape mutations can undermine the efficacy of CD8 T cell responses, allowing the virus to persist and evolve within the host.⁷³⁻⁷⁴

Prolonged exposure to HIV antigens can induce a state of immune exhaustion in CD8 T cells. Exhausted CD8 T cells exhibit functional impairment, reduced cytokine production, and an inability to effectively eliminate infected cells. The phenomenon of immune exhaustion represents a major hurdle in maintaining sustained CD8 T cell efficacy. The level of HIV replication, reflected in the viral load, directly influences the workload and effectiveness of CD8 T cells. High viral loads can overwhelm the immune system, leading to increased exhaustion and diminished CD8 T cell efficacy. Strategies aimed at reducing viral replication can positively impact CD8 T cell function. CD8 T cell responses benefit from CD4 T cell help, which includes cytokine support and direct interaction. Reduced CD4 T cell counts, a hallmark of advanced HIV infection, can compromise CD8 T cell efficacy. Strategies to preserve and restore CD4 T cell function are critical for sustaining effective CD8 T cell responses. The inflammatory microenvironment within HIV-infected tissues can influence CD8 T cell function. Persistent inflammation can contribute to immune activation and exhaustion, affecting the ability of CD8 T cells to control viral replication.⁷⁵⁻⁷⁶

CD8 Exhaustion and Dysfunction

While CD8 T cells play a crucial role in the immune response against Human Immunodeficiency Virus (HIV), prolonged exposure to the virus can lead to a state of functional exhaustion and dysfunction among these key immune effectors. CD8 T cell exhaustion is a state of functional impairment that arises in response to chronic antigen stimulation, as seen in persistent viral infections such as HIV. Exhausted CD8 T cells display reduced effector functions, diminished proliferative capacity, and an altered cytokine profile. These cells often express inhibitory receptors, further dampening

their responsiveness. Exhausted CD8 T cells upregulate inhibitory receptors, such as PD-1 (Programmed Cell Death Protein 1), CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), and TIM-3 (T-cell Immunoglobulin and Mucin-Domain Containing-3). Engagement of these receptors by their ligands on infected cells or antigen-presenting cells sends inhibitory signals, impeding CD8 T cell activation and effector functions.⁷⁵

Polyfunctionality, the ability of CD8 T cells to simultaneously produce multiple effector molecules, is a hallmark of functional T cell responses. Exhausted CD8 T cells exhibit a loss of polyfunctionality, impacting their capacity to effectively eliminate infected cells and control viral replication. Exhausted CD8 T cells experience a decline in cytotoxic capabilities. Reduced expression of cytotoxic molecules, such as perforin and granzymes, contributes to their diminished ability to induce apoptosis in infected cells. This impairment compromises the CD8 T cells' role in direct antiviral activity. Prolonged exposure to HIV antigens induces alterations in signaling pathways within CD8 T cells. Dysregulation of key signaling cascades, such as the TCR (T Cell Receptor) and cytokine signaling pathways, contributes to the functional exhaustion observed in these cells. Exhausted CD8 T cells may exhibit reduced memory potential, hindering the establishment of a robust and long-lasting immunological memory. This compromises the ability of the immune system to mount a rapid and effective response upon subsequent encounters with the virus. The presence of exhausted CD8 T cells is often associated with advanced stages of HIV infection and increased viral loads. The functional impairment of CD8 T cells contributes to an environment conducive to viral persistence and progression to acquired immunodeficiency syndrome (AIDS). While CD8 T cell exhaustion is considered a reversible state, strategies to rejuvenate exhausted CD8 T cells are actively being explored. Immune checkpoint inhibitors, which block inhibitory receptors, and therapeutic vaccines are among the approaches aimed at restoring CD8 T cell function and enhancing their efficacy in controlling HIV.⁷⁶

Therapeutic Approaches Targeting CD8 T Cells

The pivotal role of CD8 T cells in the immune response against Human Immunodeficiency Virus (HIV) has spurred the development of therapeutic strategies aimed at harnessing and enhancing the efficacy of these immune effectors. Immune checkpoint inhibitors have emerged as a promising class of therapeutics to counter CD8 T cell exhaustion. Antibodies targeting inhibitory receptors such as PD-1, CTLA-4, and TIM-3 can release the brakes on exhausted CD8 T cells, revitalizing their effector functions and enhancing their ability to control HIV. Clinical trials are underway to assess the safety and efficacy of checkpoint inhibitors in HIV treatment. Therapeutic vaccines aim to stimulate and enhance the immune response, including CD8 T cell responses, against HIV. These vaccines may incorporate viral antigens, peptides, or vectors expressing HIV proteins. Strategies include dendritic cell-based vaccines, viral vector vaccines, and nucleic acid-based vaccines. The goal is to induce a robust and durable CD8 T cell response that can effectively target and eliminate HIV-infected cells.⁷⁴

Adoptive cell therapies involve the isolation, ex vivo expansion, and reinfusion of autologous or genetically modified CD8 T cells. Chimeric Antigen Receptor T cell (CAR-T) therapy, which has shown success in cancer treatment, is being explored for its potential application in HIV. CAR-T cells engineered to express HIV-specific receptors could offer a potent and targeted approach to enhance CD8 T cell responses. While not directly targeting CD8 T cells, **Broadly Neutralizing Antibodies (bNAbs)** are monoclonal antibodies that neutralize a broad spectrum of HIV strains. By reducing viral load, bNAbs indirectly support CD8 T cell function. Combining bNAbs with strategies that enhance CD8 T cell responses may provide a synergistic approach to control HIV and delay disease progression. Administration of cytokines can modulate the immune response and enhance CD8 T cell function. Interleukin-2 (IL-2) has been investigated for its potential to boost CD8 T cell proliferation and effector functions. However,

Careful consideration of the balance between activation and potential induction of immune tolerance is essential. Recognizing the multifaceted nature of HIV infection, combination therapies that target various aspects of the immune response are being explored. Combinations of immune checkpoint inhibitors, therapeutic vaccines, and antiretroviral drugs aim to create a comprehensive and sustained immune control over the virus, including maximizing CD8 T cell efficacy. Tailoring therapeutic interventions based on individual genetic and immunological profiles is gaining attention. Precision medicine approaches seek to identify optimal treatment strategies that consider the genetic diversity and immune landscape of each patient, potentially optimizing CD8 T cell responses. While not a direct CD8 T cell-targeted therapy, ART remains a cornerstone in HIV management. By suppressing viral replication, ART provides a conducive environment for immune recovery, including the restoration of CD8 T cell function.⁷⁵⁻⁷⁶

Conclusion

The dynamic interplay between CD8 T cells and Human Immunodeficiency Virus (HIV) is a critical determinant in the course of HIV infection. This review has provided a comprehensive examination of the crucial involvement of CD8 T cells in HIV progression, encompassing their recognition mechanisms, protective effects, factors influencing efficacy, and therapeutic interventions. CD8 T cells, as immune sentinels, play a central role in recognizing and eliminating HIV-infected cells. Their direct cytotoxic effects, secretion of antiviral cytokines, and contribution to limiting viral spread underscore their significance in the host's defense against HIV.

References

- Obeagu EI, Okwuanaso CB, Edoho SH, Obeagu GU. Under-nutrition among HIV-exposed Uninfected Children: A Review of African Perspective. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):120-127.
- Obeagu EI, Alum EU, Obeagu GU. Factors associated with prevalence of HIV among youths: A review of Africa perspective. *Madonna University journal of Medicine and Health Sciences*. 2023;3(1):13-18. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/93>.
- Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences*. 2023 ;3(1):7-12. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/91>.
- Obeagu EI, Obeagu GU. An update on premalignant cervical lesions and cervical cancer screening services among HIV positive women. *J Pub Health Nutri*. 2023; 6 (2). 2023; 141:1-2. <links/63e538ed64252375639dd0df/An-update-on-premalignant-cervical-lesions-and-cervical-cancer-screening-services-among-HIV-positive-women.pdf>.
- Ezeoru VC, Enweani IB, Ochiabuto O, Nwachukwu AC, Ogbonna US, Obeagu EI. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
- Omo-Emmanuel UK, Chinedum OK, Obeagu EI. Evaluation of laboratory logistics management information system in HIV/AIDS comprehensive health facilities in Bayelsa State, Nigeria. *Int J Curr Res Med Sci*. 2017;3(1): 21-38. DOI: 10.22192/ijcrms.2017.03.01.004
- Obeagu EI, Obeagu GU, Musiimenta E, Bot YS, Hassan AO. Factors contributing to low utilization of HIV counseling and testing services. *Int. J. Curr. Res. Med. Sci*. 2023;9(2): 1-5. DOI: 10.22192/ijcrms.2023.09.02.001
- Obeagu EI, Obeagu GU. An update on survival of people living with HIV in Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;129. <links/645b4bfcf3512f1cc5885784/An-update-on-survival-of-people-living-with-HIV-in-Nigeria.pdf>.

9. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
10. Obeagu EI, Ogbonna US, Nwachukwu AC, Ochiabuto O, Enweani IB, Ezeoru VC. Prevalence of Malaria with Anaemia and HIV status in women of reproductive age in Onitsha, Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(4):10-19.
11. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng UE, Ikpeme M, Basse JO, Paul AO. TB Infection Control in TB/HIV Settings in Cross River State, Nigeria: Policy Vs Practice. *Journal of Pharmaceutical Research International*. 2020;32(22):101-119.
12. Obeagu EI, Eze VU, Alaebob EA, Ochei KC. Determination of haematocrit level and iron profile study among persons living with HIV in Umuahia, Abia State, Nigeria. *J BioInnovation*. 2016; 5:464-471. [links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/links/592bb4990f7e9b9979a975cf/DETERMINATION-OF-HAEMATOCRIT-LEVEL-AND-IRON-PROFILE-STUDY-AMONG-PERSONS-LIVING-WITH-HIV-IN-UMUAHIA-ABIA-STATE-NIGERIA.pdf).
13. Ifeanyi OE, Obeagu GU. The values of prothrombin time among HIV positive patients in FMC owerri. *International Journal of Current Microbiology and Applied Sciences*. 2015;4(4):911-916. https://www.academia.edu/download/38320140/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma2.EMMA1.pdf.
14. Izuchukwu IF, Ozims SJ, Agu GC, Obeagu EI, Onu I, Amah H, Nwosu DC, Nwanjo HU, Edward A, Arunsi MO. Knowledge of preventive measures and management of HIV/AIDS victims among parents in Umuna Orlu community of Imo state Nigeria. *Int. J. Adv. Res. Biol. Sci*. 2016;3(10): 55-65.DOI: 10.22192/ijarbs.2016.03.10.009
15. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci*. 2017;12(4):70-75. [links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf](https://www.academia.edu/links/5988ab6d0f7e9b6c8539f73d/HIV-and-TB-co-infection-among-patients-who-used-Directly-Observed-Treatment-Short-course-centres-in-Yenagoa-Nigeria.pdf)
16. Oloro OH, Oke TO, Obeagu EI. Evaluation of Coagulation Profile Patients with Pulmonary Tuberculosis and Human Immunodeficiency Virus in Owo, Ondo State, Nigeria. *Madonna University journal of Medicine and Health Sciences*. 2022;2(3):110-119.
17. Nwosu DC, Obeagu EI, Nkwocha BC, Nwanjo CA, Nwanjo HU, Amadike JN, Elendu HN, Ofoedeme CN, Ozims SJ, Nwankpa P. Change in Lipid Peroxidation Marker (MDA) and Non enzymatic Antioxidants (VIT C & E) in HIV Seropositive Children in an Urban Community of Abia State, Nigeria. *J. Bio. Innov*. 2016;5(1):24-30. [links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf](https://www.academia.edu/links/5ae735e9a6fdcc5b33eb8d6a/CHANGE-IN-LIPID-PEROXIDATION-MARKER-MDAAND-NON-ENZYMATIC-ANTIOXIDANTS-VIT-C-E-IN-HIV-SEROPOSITIVE-CHILDREN-IN-AN-URBAN-COMMUNITY-OF-ABIA-STATE-NIGERIA.pdf).
18. Igwe CM, Obeagu IE, Ogbuabor OA. Clinical characteristics of people living with HIV/AIDS on ART in 2014 at tertiary health institutions in Enugu, Nigeria. *J Pub Health Nutri*. 2022; 5 (6). 2022;130. [links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf](https://www.academia.edu/links/645a166f5762c95ac3817d32/Clinical-characteristics-of-people-living-with-HIV-AIDS-on-ART-in-2014-at-tertiary-health-institutions-in-Enugu.pdf).
19. Ifeanyi OE, Obeagu GU, Ijeoma FO, Chioma UI. The values of activated partial thromboplastin time (APTT) among HIV positive patients in FMC Owerri. *Int J Curr Res Aca Rev*. 2015; 3:139-144. https://www.academia.edu/download/38320159/Obeagu_Emmanuel_Ifeanyi3__et_al.IJCRAR.pdf.

20. Obiomah CF, Obeagu EI, Ochei KC, Swem CA, Amachukwu BO. Hematological indices o HIV seropositive subjects in Nnamdi Azikiwe University teaching hospital (NAUTH), Nnewi. Ann Clin Lab Res. 2018;6(1):1-4. [links/5aa2bb17a6fdccd544b7526e/Haematological-Indices-of-HIV-Seropositive-Subjects-at-Nnamdi-Azikiwe.pdf](https://doi.org/10.22192/ijcrms.2017.03.02.005)
21. Omo-Emmanuel UK, Ochei KC, Osuala EO, Obeagu EI, Onwuasoanya UF. Impact of prevention of mother to child transmission (PMTCT) of HIV on positivity rate in Kafanchan, Nigeria. Int. J. Curr. Res. Med. Sci. 2017;3(2): 28-34.DOI: 10.22192/ijcrms.2017.03.02.005
22. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. Health Science Reports. 2023;6(8):e1450.
23. Obeagu EI, Amekpor F, Scott GY. An update of human immunodeficiency virus infection: Bleeding disorders. J Pub Health Nutri. 2023; 6 (1). 2023;139. [links/645b4a6c2edb8e5f094d9bd9/An-update-of-human-immunodeficiency-virus-infection-Bleeding.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015).
24. Obeagu EI, Scott GY, Amekpor F, Ofodile AC, Edoho SH, Ahamefula C. Prevention of New Cases of Human Immunodeficiency Virus: Pragmatic Approaches of Saving Life in Developing Countries. Madonna University journal of Medicine and Health Sciences. 2022;2(3):128-134. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/86>.
25. Walter O, Anaebo QB, Obeagu EI, Okoroiwu IL. Evaluation of Activated Partial Thromboplastin Time and Prothrombin Time in HIV and TB Patients in Owerri Metropolis. Journal of Pharmaceutical Research International. 2022:29-34.
26. Odo M, Ochei KC, Obeagu EI, Barinaadaa A, Eteng EU, Ikpeme M, Basse JO, Paul AO. Cascade variabilities in TB case finding among people living with HIV and the use of IPT: assessment in three levels of care in cross River State, Nigeria. Journal of Pharmaceutical Research International. 2020;32(24):9-18.
27. Jakheng SP, Obeagu EI. Seroprevalence of human immunodeficiency virus based on demographic and risk factors among pregnant women attending clinics in Zaria Metropolis, Nigeria. J Pub Health Nutri. 2022; 5 (8). 2022;137. [links/6317a6b1acd814437f0ad268/Seroprevalence-of-human-immunodeficiency-virus-based-on-demographic-and-risk-factors-among-pregnant-women-attending-clinics-in-Zaria-Metropolis-Nigeria.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
28. Obeagu EI, Obeagu GU. A Review of knowledge, attitudes and socio-demographic factors associated with non-adherence to antiretroviral therapy among people living with HIV/AIDS. Int. J. Adv. Res. Biol. Sci. 2023;10(9):135-142.DOI: 10.22192/ijarbs.2023.10.09.015 [links/6516faa61e2386049de5e828/A-Review-of-knowledge-attitudes-and-socio-demographic-factors-associated-with-non-adherence-to-antiretroviral-therapy-among-people-living-with-HIV-AIDS.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.015)
29. Obeagu EI, Onuoha EC. Tuberculosis among HIV Patients: A review of Prevalence and Associated Factors. Int. J. Adv. Res. Biol. Sci. 2023;10(9):128-134.DOI: 10.22192/ijarbs.2023.10.09.014 [links/6516f938b0df2f20a2f8b0e0/Tuberculosis-among-HIV-Patients-A-review-of-Prevalence-and-Associated-Factors.pdf](https://doi.org/10.22192/ijarbs.2023.10.09.014).
30. Obeagu EI, Ibeh NC, Nwobodo HA, Ochei KC, Iwegbulam CP. Haematological indices of malaria patients coinfecting with HIV in Umuahia. Int. J. Curr. Res. Med. Sci. 2017;3(5):100-104.DOI: 10.22192/ijcrms.2017.03.05.014 https://www.academia.edu/download/54317126/Haematological_indices_of_malaria_patients_coinfected_with_HIV.pdf
31. Jakheng SP, Obeagu EI, Abdullahi IO, Jakheng EW, Chukwueze CM, Eze GC, Essien UC, Madekwe CC, Madekwe CC, Vidya S, Kumar S. Distribution Rate of Chlamydial Infection According to Demographic Factors among Pregnant Women Attending Clinics in Zaria Metropolis, Kaduna State, Nigeria. South

- Asian Journal of Research in Microbiology. 2022;13(2):26-31.
32. Viola N, Kimono E, Nuruh N, Obeagu EI. Factors Hindering Elimination of Mother to Child Transmission of HIV Service Uptake among HIV Positive Women at Comboni Hospital Kyamuhunga Bushenyi District. Asian Journal of Dental and Health Sciences. 2023;3(2):7-14. <http://ajdhs.com/index.php/journal/article/view/39>.
 33. Okorie HM, Obeagu Emmanuel I, Okpoli Henry CH, Chukwu Stella N. Comparative study of enzyme linked immunosorbent assay (Elisa) and rapid test screening methods on HIV, Hbsag, Hcv and Syphilis among voluntary donors in. Owerri, Nigeria. J Clin Commun Med. 2020;2(3):180-183. DOI: 10.32474/JCCM.2020.02.000137links/5f344530458515b7291bd95f/Comparative-Study-of-Enzyme-Linked-Immunesorbent-Assay-EIISA-and-Rapid-Test-Screening-Methods-on-HIV-HBsAg-HCV-and-Syphilis-among-Voluntary-Donors-in-Owerri-Nigeria.pdf.
 34. Ezugwu UM, Onyenekwe CC, Ukibe NR, Ahaneku JE, Onah CE, Obeagu EI, Emeje PI, Awalu JC, Igbokwe GE. Use of ATP, GTP, ADP and AMP as an Index of Energy Utilization and Storage in HIV Infected Individuals at NAUTH, Nigeria: A Longitudinal, Prospective, Case-Controlled Study. Journal of Pharmaceutical Research International. 2021;33(47A):78-84.
 35. Emmanuel G, Martin O, Peter OS, Obeagu EI, Daniel K. Factors Influencing Early Neonatal Adverse Outcomes among Women with HIV with Post Dated Pregnancies Delivering at Kampala International University Teaching Hospital, Uganda. Asian Journal of Pregnancy and Childbirth. 2023 Jul 29;6(1):203-211. <http://research.sdpublishers.net/id/eprint/2819/>.
 36. Igwe MC, Obeagu EI, Ogbuabor AO, Eze GC, Ikpenwa JN, Eze-Stephen PE. Socio-Demographic Variables of People Living with HIV/AIDS Initiated on ART in 2014 at Tertiary Health Institution in Enugu State. Asian Journal of Research in Infectious Diseases. 2022;10(4):1-7.
 37. Vincent CC, Obeagu EI, Agu IS, Ukeagu NC, Onyekachi-Chigbu AC. Adherence to Antiretroviral Therapy among HIV/AIDS in Federal Medical Centre, Owerri. Journal of Pharmaceutical Research International. 2021;33(57A):360-368.
 38. Igwe MC, Obeagu EI, Ogbuabor AO. ANALYSIS OF THE FACTORS AND PREDICTORS OF ADHERENCE TO HEALTHCARE OF PEOPLE LIVING WITH HIV/AIDS IN TERTIARY HEALTH INSTITUTIONS IN ENUGU STATE. Madonna University journal of Medicine and Health Sciences. 2022;2(3):42-57. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/75>.
 39. Madekwe CC, Madekwe CC, Obeagu EI. Inequality of monitoring in Human Immunodeficiency Virus, Tuberculosis and Malaria: A Review. Madonna University journal of Medicine and Health Sciences. 2022;2(3):6-15. <https://madonnauniversity.edu.ng/journals/index.php/medicine/article/view/69>
 40. Echendu GE, Vincent CC, Ibebuike J, Asodike M, Naze N, Chinedu EP, Ohale B, Obeagu EI. WEIGHTS OF INFANTS BORN TO HIV INFECTED MOTHERS: A PROSPECTIVE COHORT STUDY IN FEDERAL MEDICAL CENTRE, OWERRI, IMO STATE. European Journal of Pharmaceutical and Medical Research, 2023; 10(8): 564-568
 41. Nwosu DC, Nwanjo HU, Okolie NJ, Ikeh K, Ajero CM, Dike J, Ojiegbe GC, Oze GO, Obeagu EI, Nnatunanya I, Azuonwu O. BIOCHEMICAL ALTERATIONS IN ADULT HIV PATIENTS ON ANTIRETROVIRAL THERAPY. World Journal of Pharmacy and Pharmaceutical Sciences, 2015; 4(3): 153-160. [links/5a4fd0500f7e9bbc10526b38/BIOCHEMICAL-ALTERATIONS-IN-ADULT-HIV-PATIENTS-ON-ANTIRETROVIRAL-THERAPY.pdf](https://www.researchgate.net/publication/311111111).
 42. Obeagu EI, Obeagu GU. Effect of CD4 Counts on Coagulation Parameters among

- HIV Positive Patients in Federal Medical Centre, Owerri, Nigeria. *Int. J. Curr. Res. Biosci. Plant Biol.* 2015;2(4):45-49.
43. Obeagu EI, Nwosu DC. Adverse drug reactions in HIV/AIDS patients on highly active antiretroviral therapy: a review of prevalence. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2019;6(12):45-8. DOI: 10.22192/ijcreps.2019.06.12.004 links/650aba1582f01628f0335795/Adverse-drug-reactions-in-HIV-AIDS-patients-on-highly-active-antiretroviral-therapy-a-review-of-prevalence.pdf.
 44. Obeagu EI, Scott GY, Amekpor F, Obeagu GU. Implications of CD4/CD8 ratios in Human Immunodeficiency Virus infections. *Int. J. Curr. Res. Med. Sci.* 2023;9(2):6-13. DOI: 10.22192/ijcrms.2023.09.02.002 links/645a4a462edb8e5f094ad37c/Implications-of-CD4-CD8-ratios-in-Human-Immunodeficiency-Virus-infections.pdf.
 45. Obeagu EI, Ochei KC, Okeke EI, Anode AC. Assessment of the level of haemoglobin and erythropoietin in persons living with HIV in Umuahia. *Int. J. Curr. Res. Med. Sci.* 2016;2(4):29-33. links/5711c47508aeebe07c02496b/Assessment-of-the-level-of-haemoglobin-and-erythropoietin-in-persons-living-with-HIV-in-Umuahia.pdf.
 46. Ifeanyi OE, Obeagu GU. The Values of CD4 Count, among HIV Positive Patients in FMC Owerri. *Int. J. Curr. Microbiol. App. Sci.* 2015;4(4):906-910. https://www.academia.edu/download/38320134/Obeagu_Emmanuel_Ifeanyi_and_Obeagu_Getrude_Uzoma.EMMA2.pdf.
 47. Obeagu EI, Okeke EI, Anonde Andrew C. Evaluation of haemoglobin and iron profile study among persons living with HIV in Umuahia, Abia state, Nigeria. *Int. J. Curr. Res. Biol. Med.* 2016;1(2):1-5.
 48. Alum EU, Ugwu OP, Obeagu EI, Okon MB. Curtailing HIV/AIDS Spread: Impact of Religious Leaders. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):28-31.
 49. Obeagu EI, Obeagu GU, Paul-Chima UO. Stigma Associated With HIV. *AIDS: A Review*. *Newport International Journal of Public Health and Pharmacy (NIJPP)*. 2023;3(2):64-67.
 50. Alum EU, Obeagu EI, Ugwu OP, Aja PM, Okon MB. HIV Infection and Cardiovascular diseases: The obnoxious Duo. *Newport International Journal of Research in Medical Sciences (NIJRMS)*. 2023;3(2):95-99.
 51. Ibebuikwe JE, Nwokike GI, Nwosu DC, Obeagu EI. A Retrospective Study on Human Immune Deficiency Virus among Pregnant Women Attending Antenatal Clinic in Imo State University Teaching Hospital. *International Journal of Medical Science and Dental Research*, 2018; 1(2):08-14. <https://www.ijmsdr.org/published%20paper/lii2/A%20Retrospective%20Study%20on%20Human%20Immune%20Deficiency%20Virus%20among%20Pregnant%20Women%20Attending%20Antenatal%20Clinic%20in%20Imo%20State%20University%20Teaching%20Hospital.pdf>.
 52. Obeagu EI, Obarezi TN, Omeh YN, Okoro NK, Eze OB. Assessment of some haematological and biochemical parameters in HIV patients before receiving treatment in Aba, Abia State, Nigeria. *Res J Pharma Biol Chem Sci.* 2014; 5:825-830.
 53. Obeagu EI, Obarezi TN, Ogbuabor BN, Anaebo QB, Eze GC. Pattern of total white blood cell and differential count values in HIV positive patients receiving treatment in Federal Teaching Hospital Abakaliki, Ebonyi State, Nigeria. *International Journal of Life Science, Biotechnology and Pharma Research.* 2014; 391:186-189.
 54. Obeagu EI. A Review of Challenges and Coping Strategies Faced by HIV/AIDS Discordant Couples. *Madonna University journal of Medicine and Health Sciences.* 2023; 3(1): 7-12.
 55. Oloro OH, Obeagu EI. A Systematic Review on Some Coagulation Profile in HIV Infection. *International Journal of Innovative and Applied Research.* 2022;10(5):1-11.
 56. Nwosu DC, Obeagu EI, Nkwuocha BC, Nwanne CA, Nwanjo HU, Amadike JN, Ezemma MC, Okpomeshine EA, Ozims SJ,

- Agu GC. Alterations in superoxide dismutase, vitamins C and E in HIV infected children in Umuahia, Abia state. *International Journal of Advanced Research in Biological Sciences*. 2015;2(11):268-271.
57. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES)*. 2023;3(2):56-59.
 58. Ifeanyi OE, Uzoma OG, Stella EI, Chinedum OK, Abum SC. Vitamin D and insulin resistance in HIV sero positive individuals in Umudike. *Int. J. Curr. Res. Med. Sci.* 2018;4(2):104-108.
 59. Ifeanyi OE, Leticia OI, Nwosu D, Chinedum OK. A Review on blood borne viral infections: universal precautions. *Int. J. Adv. Res. Biol. Sci.* 2018;5(6):60-66.
 60. Nwovu AI, Ifeanyi OE, Uzoma OG, Nwebonyi NS. Occurrence of Some Blood Borne Viral Infection and Adherence to Universal Precautions among Laboratory Staff in Federal Teaching Hospital Abakaliki Ebonyi State. *Arch Blood Transfus Disord*. 2018;1(2).
 61. Chinedu K, Takim AE, Obeagu EI, Chinazor UD, Eloghosa O, Ojong OE, Odunze U. HIV and TB co-infection among patients who used Directly Observed Treatment Short-course centres in Yenagoa, Nigeria. *IOSR J Pharm Biol Sci.* 2017;12(4):70-75.
 62. Offie DC, Obeagu EI, Akueshi C, Njab JE, Ekanem EE, Dike PN, Oguh DN. Facilitators and barriers to retention in HIV care among HIV infected MSM attending Community Health Center Yaba, Lagos Nigeria. *Journal of Pharmaceutical Research International*. 2021;33(52B):10-19.
 63. Obeagu EI, Obeagu GU, Ede MO, Odo EO, Buhari HA. Translation of HIV/AIDS knowledge into behavior change among secondary school adolescents in Uganda: A review. *Medicine (Baltimore)*. 2023;102(49): e36599. doi: 10.1097/MD.0000000000036599. PMID: 38065920; PMCID: PMC10713174.
 64. Anyiam AF, Arinze-Anyiam OC, Ironde EA, Obeagu EI. Distribution of ABO and rhesus blood grouping with HIV infection among blood donors in Ekiti State Nigeria. *Medicine (Baltimore)*. 2023;102(47): e36342. doi: 10.1097/MD.0000000000036342. PMID: 38013335; PMCID: PMC10681551.
 65. Echefu SN, Udosen JE, Akwiwu EC, Akpotuzor JO, Obeagu EI. Effect of Dolutegravir regimen against other regimens on some hematological parameters, CD4 count and viral load of people living with HIV infection in South Eastern Nigeria. *Medicine (Baltimore)*. 2023;102(47): e35910. doi: 10.1097/MD.0000000000035910. PMID: 38013350; PMCID: PMC10681510.
 66. Opeyemi AA, Obeagu EI. Regulations of malaria in children with human immunodeficiency virus infection: A review. *Medicine (Baltimore)*. 2023;102(46): e36166. doi: 10.1097/MD.0000000000036166. PMID: 37986340; PMCID: PMC10659731.
 67. Alum EU, Obeagu EI, Ugwu OPC, Samson AO, Adepoju AO, Amusa MO. Inclusion of nutritional counseling and mental health services in HIV/AIDS management: A paradigm shift. *Medicine (Baltimore)*. 2023;102(41): e35673. doi: 10.1097/MD.0000000000035673. PMID: 37832059; PMCID: PMC10578718.
 68. Aizaz M, Abbas FA, Abbas A, Tabassum S, Obeagu EI. Alarming rise in HIV cases in Pakistan: Challenges and future recommendations at hand. *Health Sci Rep*. 2023;6(8): e1450. doi: 10.1002/hsr2.1450. PMID: 37520460; PMCID: PMC10375546.
 69. Obeagu EI, Obeagu GU, Obiezu J, Ezeonwumelu C, Ogunnaya FU, Ngwoke AO, Emeka-Obi OR, Ugwu OP. Hematologic Support in HIV Patients: Blood Transfusion Strategies and Immunological Considerations. *APPLIED SCIENCES (NIJBAS)*. 2023;3(3).
 70. Obeagu EI, Ubosi NI, Uzoma G. Storms and Struggles: Managing HIV Amid Natural Disasters. *Int. J. Curr. Res. Chem. Pharm. Sci.* 2023;10(11):14-25.

71. Obeagu EI, Obeagu GU. Human Immunodeficiency Virus and tuberculosis infection: A review of prevalence of associated factors. *Int. J. Adv. Multidiscip. Res.* 2023;10(10):56-62.
72. Obeagu EI, Malot S, Obeagu GU, Ugwu OP. HIV resistance in patients with Sickle Cell Anaemia. *Newport International Journal of Scientific and Experimental Sciences (NIJSES).* 2023;3(2):56-9.
73. Alum EU, Ugwu OP, Obeagu EI, Aja PM, Okon MB, Uti DE. Reducing HIV Infection Rate in Women: A Catalyst to reducing HIV Infection pervasiveness in Africa. *International Journal of Innovative and Applied Research.* 2023;11(10):01-6.
74. Chan YT, Cheong HC, Tang TF, Rajasuriar R, Cheng KK, Looi CY, Wong WF, Kamarulzaman A. Immune Checkpoint Molecules and Glucose Metabolism in HIV-Induced T Cell Exhaustion. *Biomedicines.* 2022;10(11).
75. Gerlach C, Rohr JC, Perié L, Van Rooij N, Van Heijst JW, Velds A, Urbanus J, Naik SH, Jacobs H, Beltman JB, de Boer RJ. Heterogeneous differentiation patterns of individual CD8+ T cells. *Science.* 2013;340(6132):635-639.
76. Perdomo-Celis F, Taborda NA, Rugeles MT. CD8+ T-cell response to HIV infection in the era of antiretroviral therapy. *Frontiers in immunology.* 2019; 10:1896.

Access this Article in Online	
	Website: www.ijcrims.com
Quick Response Code	Subject: Medical Sciences

How to cite this article:

Emmanuel Ifeanyi Obeagu and Getrude Uzoma Obeagu. (2024). The Crucial Involvement of CD8 in HIV Progression: A Review. *Int. J. Curr. Res. Med. Sci.* 10(2): 15-25.

DOI: <http://dx.doi.org/10.22192/ijcrms.2024.10.02.003>